NCT01898663View on ClinicalTrials.gov

DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
High-risk Soft Tissue Sarcoma
Interventions
BIOLOGICAL

Adenovirus-transfected DC + CIK

Adenovirus-transfected autologous DC vaccine plus CIK cells

Trial Locations (1)

100071

RECRUITING

Department of Hematopoietic Stem Cell Transplantation, Beijing

All Listed Sponsors
lead

Affiliated Hospital to Academy of Military Medical Sciences

OTHER